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Abstract
Background:  Though the dysfunction of central dopaminergic system has been proposed, the
etiology or pathogenesis of schizophrenia is still uncertain partly due to limited accessibility to
dopamine receptor. The purpose of this study was to define whether or not the easily accessible
dopamine receptors of peripheral lymphocytes can be the peripheral markers of schizophrenia.
Results:  44 drug-medicated schizophrenics for more than 3 years, 28 drug-free schizophrenics
for more than 3 months, 15 drug-naïve schizophrenic patients, and 31 healthy persons were
enrolled. Sequential reverse transcription and quantitative polymerase chain reaction of the mRNA
w e r e  u s e d  t o  i n v e s t i g a t e  t h e  e x p r e s s i o n  o f  D 3  a n d  D 5  d o p a m i n e  r e c e p t o r s  i n  p e r i p h e r a l
lymphocytes. The gene expression of dopamine receptors was compared in each group. After
taking antipsychotics in drug-free and drug-naïve patients, the dopamine receptors of peripheral
lymphocytes were sequentially studied 2nd week and 8th week after medication.
In drug-free schizophrenics, D3 dopamine receptor mRNA expression of peripheral lymphocytes
significantly increased compared to that of controls and drug-medicated schizophrenics, and D5
d o p a m i n e  r e c e p t o r  m R N A  e x p r e s s i o n  i n c r e a s e d  c o m p a r e d  t o  t h a t  o f  d r u g - m e d i c a t e d
schizophrenics. After taking antipsychotics, mRNA of dopamine receptors peaked at 2nd week,
after which it decreases but the level was above baseline one at 8th week. Drug-free and drug-naïve
patients  were  divided  into  two  groups  according  to  dopamine  receptor  expression  before
medications, and the group of patients with increased dopamine receptor expression had more
severe psychiatric symptoms.
Conclusions:   T h e s e  r e s u l t s  r e v e a l  t h a t  t h e  m o l e c u l a r  b i o l o g i c a l l y - d e t e r m i n e d  d o p a m i n e
receptors of peripheral lymphocytes are reactive, and that increased expression of dopamine
receptor  in  peripheral  lymphocyte  has  possible  clinical  significance  for  subgrouping  of
schizophrenis.
Background
Schizophrenia, commonly developed in adolescents and
young adults, is one of the most common mental disor-
ders, but the pathophysiology and etiology of schizo-
phrenia is still obscure. Numerous studies on dopamine
and schizophrenia have suggested that the change in the
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dopamine system is related to schizophrenia, but there is
little direct evidence for the "dopamine hypothesis in
schizophrenia". Recent progress in molecular biology
and imaging techniques has enabled new insight for
schizophrenia research, but these methods are still limit-
ed by their availability and often reveal inconsistent re-
sults. The "dopamine hypothesis" is largely based on
pharmacological manipulation of the dopamine system,
either by mimicking [1,2] or reducing the symptoms of
schizophrenia [3]. However changes in the dopamine
system are influenced not only by dopamine itself, but
also by dopamine receptors. Therefore, to elucidate the
exact changes in the dopamine system researches about
the relationship between dopamine and dopamine re-
ceptors are needed.
In the early 1980s, Le Fur reported the existence of high
affinity binding sites for [3H]spiroperidol in lymphocyte
of peripheral blood [4], but there has been long debate as
to whether these sites are true dopamine receptors or
nonspecific binding sites. Recent progress in molecular
biology reveals the existence of mRNA of D3, D4, D5
dopamine receptors in peripheral lymphocytes, thereby
suggesting that the binding sites for [3H]spiroperidol in
peripheral lymphocytes may be true dopamine receptors
[5,6,7]. However, the clinical significance of these find-
ings, and whether or not these receptors reflect central
dopamine receptors remains uncertain.
The purposes of this study were to examine if the mRNA
of peripheral dopamine receptor is statically or dynami-
cally changed in schizophrenia, and whether or not these
receptors have some value as a potential peripheral
marker reflecting central one in schizophrenia.
Materials and methods
Subjects
The total number of subjects was 87 schizophrenic pa-
tients. 44 of them were chronic schizophrenics who had
been taking antipsychotic drugs for more than 3 years
(drug-med patients), 28 were drug-free schizophrenics
who had not taken antipsychotic drugs for more than 3
months (drug-free patients), and 15 were drug-naïve
schizophrenics who had never taken antipsychotic drugs
(drug-naïve patients). For the controls, age and sex
matched 31 healthy persons were enrolled. All patients
fulfilled the DSM-IV criteria and the patients with a pre-
vious history of neurologic, neuropsychologic, medical,
and surgical disease were excluded. The demographic
data of subjects were shown at the Table 1.
Methods
Study design
Before taking antipsychotics, clinical scale and the
amount of dopamine receptor mRNA were checked in
the group of schizophrenics and the amount of dopamine
receptor mRNA was checked in controls. At 2nd week
and 8th week after taking antipsychotics, the the amount
of dopamine receptor mRNA were re-checked in drug-
free and drug-naïve patients.
To assess the psychiatric pathology of patients, the Brief
Psychiatric Rating Scale (BPRS) was adopted [8] and Ex-
trapyramidal Symptom Rating Scale (ESRS) was used to
assess the drug side effects [9].
Table 1: Demographic data of study groups
Control Drug-med pts Drug-free Drug-naïve
(N=31) (N=44) pts(N=28) pts(N=15) p-value**
Age* 33.9 ±  9.5 37.3 ±  11.4 35.1 ±  9.130.8  ±  7.7 NS***
Sex Male 17 33 6 16 NS***
Female 14 11 9 15
Age of symptom onset* 22.5 ±  6.8 26.7 ±  9.2 28.1 ±  7.8 NS***
Duration of illness* 12.7 ±  8.3 7.6 ±  5.2 2.5 ±  3.0 <0.01
TBPRS 36.1 ±  12.9 41.9 ±  25.4 36.9 ±  18.2 NS***
Dose of antipsychotics**** 1000.1 ±  130.4 769.6 ±  491.2 614.2 ±  234.7 NS***
Duration of no-medication 10.61 ±  7.01
(mean months ±  SD)
* :mean ±  standard deviation (years) ** :one-way ANOVA test, independent T-test, Chi-square test *** :NS; statistically non-significant **** :chlorpro-
mazine equivalent dose (mg/cay)BMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
Quantitation of dopamine receptor mRNA
1) preparation of blood lymphocyte
Peripheral blood samples were placed on Ficoll-Paque
(Pharmacia, Sweden) gradients and the centrifuged for
15 minutes. Separation of lymphocytes was done no later
than 6 hours after drawing blood.
2) extraction of total RNA and reverse transcription
Total RNAs were extracted from lymphocytes by RNeasy
Total RNA kit (Quiagen, Germany). 2 µ g of total RNA ex-
tracted from lymphocytes was reverse transcribed into
first-strand cDNA with 1 µ g of random hexanucleotide
and 200 units of Molony murine leukemia virus reverse
transcriptase (GibcoBRL, Gaithersburg) in a 20 µ l final
volume.
3) oligonucleotide primer used for PCR amplification
The oligonucleotid primers used for PCR amplification
of D3 dompamine receptor (D3R), D5 dopamine recep-
tor (D5R), beta-actin (β A) as internal controls, and mu-
tant template for competition of each products as
external control were synthesized using a nucleotide syn-
thesizer. Their sequences were shown at the Table 2.
4) Quantitative RT-PCR
Mutant D3R primers were used in PCR amplification
with the mimic DNA fragment provided in PCR MIMIC
construction kit (Clontech, USA) to create PCR tem-
plates with gene-specific 5'and 3' ends for D3R, then
these templates were amplified and purified. These
products were quantified and diluted before being used
as competitive external standard. With the same tech-
nique, mutant templates for D5R and β A were synthe-
sized. At various concentrations of mutant template,
PCR amplification was performed from 75 ng cDNA with
5 µ l PCR buffer (PH8.5, 2.5 mM MgCl2), 4 µ l 1.25 mM
dNTP, 0.2 µ l (5 U/µ l) Taq DNA polymerase, 9.8 µ l dis-
tilled water, 1 µ l upstream and downstream D3 or D5
primer in 10 µ l final volume. PCR was carried out in a
DNA thermal cycler (GeneAmp PCR system 9600, Per-
kin Elmer, USA) after first denaturation at 94° C for 3
minutes, and each cycle consisted of denaturation at
94° C for 40 seconds, annealing at 59° C for 40 seconds,
and extension at 72° C for 80 seconds. The number of to-
Table 2: Primer used to amplify the dopamine receptor, beta-actin and their competitive mutants
product
Target Primer primer sequence length (bp)
D3R Upstream 5'-ACG-ACA-TGG-CTG-GGC-TAC-G-3' 155
Downstream 5' -GCC-AAC-AGC-CTG-GCG-CTA-G-3'
D5R Upstream 5'-GTC-GCC-GAG-GTG-GCC-GGT-TAC-3' 362
Downstream 5'-GCT-GGA-GTC-AGA-ATT-CTC-TGC-AT-3'
BA Upstream 5'-CGT-GGG-CCG-CCC-TAG-GCA-CCA-3' 260
Downstream 5'-TTG-GCC-TTA-GGG-TTC-AGG-GGG-G-3'
Mutant D3R Upstream 5' -TCA-AGA-GTT-CCC-TAT-CAC-TCT-CAA-GTT- 474
TCG-TGA-GCT-GAT -TG-3'
Down stream 5'-GTC-GCC-GAG-GTG-GCC-GGT-TAC-CAA-GTT-
TCG-TGA-GCT-GAT -TG-3'
Mutant D5R Upstream 5'-GTC-GCC-GAG-GTG-GCC-GGT-TAC-CAA-GTT- 435
TCG-TGA-GCT-GAT -TG-3'
Downstream 5'-GCT-GGA-GTC-AGA-ATT-CTC-TGC-ATA-TTT-
GAT-TCT-GGA-CCA-TGG-C-3'
Mutant β A Upstream 5'-TTG-GCC-TTA-GGG-TTC-AGG-GGG-GAT-TTG- 429
ATT-CTG-GAC-CAT-GGC-3'
Downstream 5'-CGT-GGG-CCG-CCC-TAG-GCA-CCA-CAA-GTT-
TCG-TGA-GCT -GAT-TG-3'
Table 3: Influence of clinical factors on D3R/β A, D5R/β A mRNA 
ratio in drug-med patients
Sex Age Onset duration BPRS dose
D3R/β AN S * NS* NS* NS* NS* NS*
D5R/β AN S * NS* NS* NS* NS* NS*
*: NS; statistically non-significantBMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
tal PCR cycle was 37. PCR for β A was carried out for 27
cycles and each cycle was consisted of denaturation at
94° C for 30 seconds, annealing at 59° C for 30 seconds,
and extention at 72° C for 1 minute. For quantitative anal-
ysis, each 10 µ l of PCR products were examined by elec-
trophoresis on 1.5% agarose gel containing 0.5 µ g/ml
ethidium bromide, and optical density was quantitated
by using densitometric scanning imaging system (CSC;
chemicoluminence detection module 1.0 and TINA 2.0
program, Raytest, Belmont, CA, USA). Let the logarith-
mic value of concentration of D3 mutant template at x
axis and logarithmic value of mutant-product ratio (opti-
cal density of D3R mutant template / optical density of
D3R) at y axis, then regression equation was done. Same
procedure was done for D5R and β A. Quantitative analy-
sis of each sample was done if the coefficient value was
more than 0.9. Expected concentration value of D3R,
D5R, β A was the X value of 0 point in the Y axis (Figure
1, Figure 2). To confirm reliability of these methods, con-
centration of D3R was plotted on a semilogarthmic scale
against the amount of cDNA and checked whether this
curve was in linear relation. To confirm reproducibility,
random samples of 14 patients were checked twice, and
the results were compared with each other.
Statistical test
Statistical determinations were performed by using a
statistical program (SPSS version 8.0). Mann-Whitney
test, independent T-test, Chi-square test, Pearson corre-
lation, multiple regression analysis. One-way ANOVA
test, and repeated measure of ANOVA were chosen.
Results
Test for sensitivity and reproducibility of methodology
To confirm sensitivity and reproducibility, the D3R,
D5R, β A products amplified by RT-PCR technique were
electrophoresed on 1.5% agarose gels, and the OD was
plotted on the X axis against the amount of cDNA used in
PCR on the Y axis. This curve was linear (Figure 3).
Concentrations of D3R randomly sampled in 14 patients
were checked twice by the same technique for reproduc-
ibility. The results were statistically identical (Cron-
bach's alpha is 0.92). Therefore, RT-PCR was reliable
tool for quantitation of mRNA.
Figure 1
Examples of quantitative RT-PCR of D3R mRNA in one patient.  Upper band represents the D3R mutant that com-
petes with D3R cDNA (lower band). This figure shows lane 3 has approximately equal concentrations of D3R and D3R
mutant.
Figure 2
Analysis of actual D3R mRNA concentraion of Figure
1. The exact concentrations of the patient in Figure 1a. were
shown. The 0 point on the Y axis represents equal concen-
trations  of  D3R  and  D3R  mutant,  and  the  corresponding
point on the X axis represents the actual value of D3R (loga-
rithmic value).BMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
Quantitation of dopamine receptor mRNA among study 
groups
1) Analysis of factors for quatitation of D3R/β A, D5R/β A
Multiple regression was done to confirm whether gen-
der, age in normal healthy controls, and the symptom
onset, prevalence period, dosage of antipsychotics, BPRS
score in drug-med patients were influential factors. All
the factors were not statistically significant. (Table 3).
2) Comparison of D3R/β A, D5R/β A among study groups 
before taking antipsychotics
D3R mRNA expression of peripheral lymphocytes was
significantly increased in drug-free patients, compared
to controls and drug-med patients. There was no differ-
ence between controls and drug-med patients. A few
drug-naïve patients also revealed increased D3R and
D5R mRNA expression, but without statistical signifi-
cance compared to controls (Figure 4, Figure 5, Table 4).
The D5R/β A ratio was significantly elevated between
drug-free patients and drug-med patients, but there was
no statistical difference between drug-free patients and
normal controls (Figure 5).
3) The relationship between D3R/β A, D5R/β A and drug 
free duration in drug-free patients
To analyze the relationship between elevated dopamine
receptor mRNA and the drug-free duration in drug-free
patients, the D3R/β A, D5R/β A ratio was plotted against
the drug-free duration. Statistical test showed no signifi-
cant difference between D3R/β A, D5R/β A ratio and
drug-free duration (Figure 6, Figure 7).
4) Relationship between amount of D3R/β A and clinical 
profile
According to the amount of D3R/β A, the drug-free and
drug-naïve patients were divided into two groups. The
high dopamine receptor group had higher D3R/β A ratio
than that of normal controls (more than 2 standard devi-
ation), while other patients were classified in the normal
dopamine receptor group. The two groups were com-
pared with BPRS scale and ESRS scale. 10 of 28 drug-
free patients, and 3 of 15 naïve patients were included in
the high dopamine receptor group. The patients of the
high dopamine receptor group had statistically signifi-
cant high BPRS compared to the patients in the normal
dopamine receptor group, but there was no difference
between the two group in ESRS (Table 5).
Figure 3
D3R mRNA standard curve. Linear correlation is shown
between template cDNA and D3R mRNA. This finding rep-
resents the sensitivity and reproducibility of the methodolog-
ical technique.
Table 4: D3R/β A, D5R/β A mRNA ratio between normal and 
schizophrenic patients (mean ±  standard error)
Normal Drug-med 
pts
Drug-
free pts
Drug-na-
ive pts
p-value*
D3R/β A2 . 10   ±  
0.47**
2.09 ±  
0.63**
19.45 ±  
5.57**
7.75 ±  
3.21
p < 0.05
D5R/β A 0.37 ±  
0.10
0.19 ±  
0.05**
0.78 ±  
0.21**
0.58 ±  
0.16
p < 0.05
* :One-way ANOVA test, Post-hoc test (Bonferroni test) ** :p < 0.05
Figure 4
D3R/β A  mRNA  among  study  groups.  In  drug-free
patients, D3R/β A was higher than that of normal or on-med
patients. There was no difference between normal and on-
med patientsBMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
5) Change of dopmaine receptor mRNA after antipsycotics
After taking antipsychotics, dopamine receptor mRNA
peaked at 2nd week, after which it decreased, but the lev-
el of this was above baseline one at 8th week (Table 6).
Discussion
Dopamine and Dopaminergic neurons are localized in
certain parts of the central nervous system and involved
in the pathophysiology of schizophrenia. However, there
is no direct evidence of dysfunction of brain dopaminer-
gic systems in schizophrenic patients because no pathog-
nomic change in the dopaminergic system has been
found at autopsy and the direct assessment of brain
dopaminergic systems in vivo is almost impossible at
present. In addition, abnormal function of the dopamine
system results not only from the dopamiergic neuron,
but from dopamine receptors and these dopamine recep-
tors can be changed secondly by dopamine. Therefore,
the importance of the physiological and pathological
roles of dopamine receptors is emerging.
Recent progress in molecular biology has revealed 5 dis-
tinct subtypes of dopamine receptors, and their structure
and physiological functions have been identified. Owing
to this advance, receptors other than D2 dopamine re-
ceptors, which is traditionally considered to be impor-
tant in pathophysiology of schizophrenia, have been
issued in relation to schizophrenia [10,11,12]. Among
these other dopamine receptors, the D3 dopamine recep-
tor is primarily localized in the limbic area, has a high af-
finity for antipsychotics, and it has been found to be
elevated in postmortem study of schizophrenic patients
[13]. As a result, the D3 dopamine receptor is considered
to be important in the pathophysiology of schizophrenia.
Therefore, the notion that the effect of antipsychotic
medication is more closely related to D3 dopamine re-
ceptors, while extrapyramidal drug side effects are relat-
ed to the D2 dopamine receptor, is one of the modified
dopamine hypotheses [14,15].
The D5 dopamine receptor, belongs to the Dl dopamine
receptor subfamily, has a similar nucleotide sequence to
the Dl receptor [16], and a high affinity for dopamine
more than the Dl dopamine receptor [17]. The D5
dopamine receptor, which is sparse in area of the Dl
dopamine receptor, is mainly localized in the hippocam-
pus, thalamus, and its physiological role is still uncertain
[18]. However, some report suggest that the Dl
dopamine receptor may be related in negative symptom
[19,20] and the fact that the D5 dopamine receptor in the
prefrontal cortex is down-regulated by antipsychotics in
animal experiment [21] may suggest that the D5
dopamine receptor is also related to schizophrenia.
Nigrostriatal and mesolimbic dopaminergic pathways
are major dopaminergic systems in the brain. D3
dopamine receptor has a high affinity for dopamine [22],
and is preferentially localized in mesolimbic dopamine
system, and it projects to the ventral striatum. This re-
ceptor is considered to have a major role in cognition and
Table 5: Comparison of clinical profiles according to the level of 
dopamine receptor mRNA before medication (mean ±  SD)
High dopamine R Normal 
dopamine R
p-value*
(N=13) (N=30)
BPRS 54.08 ±  34.70 34.47 ±  13.43 <0.05
ESRS 1.58 ±  2.78 3.25 ±  7.09 0.561
* :Mann-Whitne test
Table 6: Sequential studies of off-medication patients after antip-
sychotic medication (mean ±  standard error)
0 week 2 week 8 week
Drug-free 
Pts
D3R/β A 19.45 ±  
5.57
26.74 ±  6.4122.01  ±  6.19
D5R/β A 0.78 ±  0.211 .88 ±  0.90 1.62 ±  0.82
Drug-naïve D3R/β A 7.75 ±  3.211 9.42 ±  5.17 14.11 ±  7.23
pts
D5R/β A 0.58 ±  0.16 1.21 ±  0.510.74  ±  0.50
Figure 5
D5R/β A mRNA among study groups. There were simi-
lar findings with figure 3, but there is no significant difference
among groups.BMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
emotion [23]. Therefore, changes of D3 dopamine recep-
tors mediate the changes in the striato-pallidal-thalamo-
cortical limbic loop, and these changes are considered to
be involved in the symptoms and pathophysiology of
schizophrenia [24]. While the nigrostriatal system and
D2 dopamine receptors have a major role in pathophysi-
ology in Parkinson's disease, the mesolimbic system and
D3 dopamine receptor may be more involved in the
pharmacological responsiveness and pathophysiology of
schizophrenia.
A major limitation of the dopamine hypothesis in schiz-
ophrenia is that there are no suitable in vivo methods for
direct assessment of functional changes of the dopamine
system in the brain. Though positron emission tomogra-
phy (PET) can assess D2 dopamine receptors in striatum
[25], PET has limited usability other than striatum, and
limbic area and cortex related to schizophrenia is diffi-
cult to assess by PET. To assess the changes in dopamine
receptors, an easily accessible peripheral marker is need-
ed, and the dopamine receptor of peripheral lymphocyte
may be a possible candidate. However, small quantity of
mRNA of dopamine receptors in the peripheral lym-
phocyte is a major limitation to research assessing clini-
cal significance. Methods to quantitate gene expression
are Northern blot, RNase protection assay, in situ hy-
bridization, and RT-PCR. Though Northern blot and
RNase protection assay are classical tools, the more sen-
sitive RT-PCR is useful in detecting small quantities. In
RT-PCR, as the reaction cycle increases, product is expo-
nentially increased. While this exponential increase
causes high sensitivity, if not adequately controlled, the
initial amount is not precisely assessed. To solve this
problem, PCR is done with a primer for a non-competi-
tive endogenous target (β A) as an internal control (mul-
tiplex PCR) or with competitive external strands as an
external control. For a more accurate assessment, each
β A, D3, D5 was quantitated by the addition of a compet-
itive external strand, then the dopamine receptor/β A ra-
tio was done. Since all dopamine receptors and most
other receptors related to the G-protein have a similar
structure, designing a sensitive and specific primer is
critical in performing quantitative RT-PCR. The D3
dopamine receptor especially has a splicing variant with-
out physiological function [6]. Therefore, a sensitive and
specific primer for quantitation of the intact form of D3
dopamine receptors is important.
Considering the changes in dopamine receptors after
taking antipsychotics, these receptors may have a physi-
ological role, but the relationship between peripheral
and central dopamine receptors is still uncertain. In ani-
mal experiment, Shenkman concluded that cholinergic
muscarine receptors in peripheral lymphocytes are use-
ful markers for cholinergic muscarine bindings in the
brain [26]. Dopamine receptors and cholinergic mus-
carine receptors are all typical G-protein related recep-
tors, and there was a report that D3 mRNA in
lymphocyte is decreased in Parkinson's disease, and that
the degree of decrease was correlated with the severity of
this disease [27]. Considering all the above findings,
dopamine receptors in peripheral lymphocyte can be a
peripheral marker of central nervous system dopamine
receptors. However, there are various expressions of
subtypes of dopamine receptors and these show various
responses to antipsychotics according to the anatomic
substrate in the central nervous system [13, 28]. D3
dopamine receptors in lymphocytes can reflect particu-
lar anatomy in the brain, not merely the whole brain, and
considering the previous result from a report on D3
Figure 6
Relationship between D3R/β A and drug-free duration
in  drug-free  patients.  To  analyze  the  cause  of  high
dopamine  receptor  in  drug-free  patients,  the  relationship
between D3R/β A and drug-free duration is shown. Though
negative correlation may be suggested, it was not statistically
significant.
Figure 7
Relationship between D5R/β A and drug-free duration
in  drug-free  patients.  In  D5R/β A,  similar  findings  were
shown with D3R/β A.BMC Medical Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2350/2/3
dopamine receptor [13] and a dense population of D3 re-
ceptor in the limbic striatum, limbic striatum may be a
plausible corresponding site.
In this study, D3 dopamine receptor mRNA was in-
creased in drug-free patients compared to drug-med pa-
tients and controls, while somewhat lower levels of D3
dopamine receptor mRNA were found in chronically
medicated patients compared to normal controls before
taking antipsychotics. The fact that D3 dopamine recep-
tor mRNA is elevated in medicated schizophrenic pa-
tients produced similar findings to the report of
Gureivch (1997). But after taking antipsychotics,
dopamine receptor mRNA peaked at 2nd week, while at
8th week dopamine receptor mRNA had decreased,
though the level was still found to be above normal con-
trols. Though long term follow up was not done, consid-
ering that dopamine receptor mRNA decreased in
chronically medicated patients, dopamine receptor
mRNA might decrease to lower levels than that of the
control patients.
The difference between drug-free patients and naïve pa-
tients is interesting. While dopamine receptor mRNA in
drug-free patients is higher than in normal controls, the
level of drug-naïve patients, though it increased, is not a
statistically higher one. This may be interpreted in two
ways:
First, the residual drug effect of antipsychotics due to a
short withdrawal period may influence drug-free pa-
tients. We analyzed it by correlation with drug withdraw-
al periods and dopamine receptor mRNA in drug-free
patients. The coefficient value is not statistically signifi-
cant. It is not exactly known how rapidly D2-like recep-
tors return to normal after neuroleptic treatment, but
PET study showed that there is no residual increase of
dopamine receptor in striatum within a month period of
drug withdrawal [29]. Therefore this assumption may be
less possible.
Second, there is the possibility of in-born elevation of
lymphocyte dopamine receptors in certain schizophrenic
patients and the possibility of subgrouping of schizo-
phrenia. To elucidate this possibility, we analyzed drug-
free and drug-naïve patients in two groups according to
levels of dopamine receptors and compared these two
groups with their clinical character. The patients in the
high dopamine receptor group had statistically signifi-
cant high BPRS compared to that of patients in the nor-
mal dopamine receptor group. But there was no
difference between the two group in ESRS before taking
antipsychotics (Table 5). There has been a long debate
about the subgrouping of schizophrenia [30] and the
lack of biological markers for this hypothesis is a major
limitation. The peripheral dopamine receptor may be a
possible candidate for this hypothesis. But due to the
small number of study groups, and the limitations of oth-
er confounding factors, somewhat cautious conclusions
are needed.
We believe a latter interpretation is more plausible but
stricter and more prudent prospective study design is
necessary before reaching more convincing conclusions.
This study indicated that dopamine receptors in periph-
eral lymphocytes are elevated in certain populations of
schizophrenic patients compared to controls before tak-
ing antipsychotics, and dynamically changed after taking
antipsychotics. Therefore dopamine receptor in periph-
eral lymphocyte may be an easily accessible candidate for
a biological marker and studying a pharmacodynamic
study in a future.
Conclusion
This study reveals that the molecular biologically-deter-
mined dopamine receptors of peripheral lymphocytes
are reactive after taking antipsychotics, and that in-
creased expression of dopamine receptor in peripheral
lymphocyte has possible clinical significance for sub-
grouping of schizophrenis.
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